This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
MEDLINE, HealthSTAR and the Cochrane Database of Systematic Reviews were searched.
Criteria used to ensure the validity of primary studies
Although the authors commented that they relied most heavily on those studies with highest quality, they did not report any criteria used to assess the validity of the primary studies.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Seventy studies were included in the review.
Methods of combining primary studies
The authors used data from the included studies selectively. The range of results coming from the included studies was used in the sensitivity analysis as a range for some of the parameters.
Investigation of differences between primary studies
The authors did not investigate differences between the primary studies.
Results of the review
The following values were included as parameters of the model: the probability that the cause of dyspepsia is NUD, 66%; the probability that NUD is H. pylori positive, 48%; the probability that the cause of dyspepsia is PUD, 23%; the probability that PUD is H. pylori positive, 90%; the probability that the cause of dyspepsia is oesophagitis, 10%; the probability that oesophagitis is H. pylori positive, 40%; the probability that cause of dyspepsia is gastric cancer, 0.5%; the probability that gastric cancer is H. pylori positive, 85%; the probability that the first round of antibiotic therapy successfully eradicates H. pylori, 85%; the probability that the second round of antibiotic therapy successfully eradicates H. pylori, 80%; the probability that a patient with NUD has initial symptom improvement 1 year after anti-H. pylori therapy, 48%; the probability that a patient with NUD has sustained symptom improvement 1 year after anti-H. pylori therapy, 33%; the probability that a patient with PUD has initial symptom improvement with anti-H. pylori therapy, 85%;
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Page: 3 / 8 the probability that a patient with PUD has sustained symptom improvement 1 year after anti-H. pylori therapy, 70%; the probability that a patient with oesophagitis has initial symptom improvement with anti-H. pylori therapy, 25%; the probability that a patient with NUD has initial improvement with the PPI trial, 38%; the probability that a patient with PUD has initial symptom improvement with the PPI trial, 80%; the probability that a patient with PUD has sustained symptom improvement after 1 year of continuous PPI therapy, 75%; the probability that a patient with oesophagitis has initial symptom improvement with the PPI trial, 80%; the probability that a patient with oesophagitis has sustained symptom improvement after 1 year of continuous PPI therapy, 70%; the probability that a patient with gastric cancer has initial symptom improvement with the PPI trial, 33%.
Methods used to derive estimates of effectiveness
The authors formulated several assumptions to derive some of the effectiveness estimators.
Estimates of effectiveness and key assumptions
The authors assumed the following: the probability that a patient with oesophagitis has sustained symptom improvement after 1 year of anti-H. pylori therapy was 15%; the probability that a patient with gastric cancer has initial symptom improvement with anti-H. pylori therapy was 10%; the probability that a patient with gastric cancer has sustained symptom improvement after 1 year of continuous PPI therapy was 2%; the probability that a patient with NUD has sustained symptom improvement with the PPI trial was 28%; and the probability that a patient with gastric cancer has sustained symptom improvement 1 year after anti-H. pylori therapy was 2%.
Measure of benefits used in the economic analysis
The measures of benefits used were the quality-adjusted life-years (QALYs) and the number of symptom-free patients after 1 year. The utilities from mild, moderate and severe dyspepsia symptoms were obtained from a study that used the time trade-off method in a sample of 73 patients. These utilities were combined to calculate base-case QALYs, assuming that 50% of the cohort had severe dyspepsia, 25% had moderate dyspepsia and 25% had mild dyspepsia.
Direct costs
The cost/resource boundary adopted was that of a third-party payer. The broad expenditure areas were drug costs, diagnostic procedure costs, endoscopic costs and physicians' fees. Most of the resources used were reported separately from the costs, or could be easily derived from the data reported in the paper. The source of the resource use data was not reported. The drug costs were collected from the 2000 Red Book of average wholesale prices for pharmaceuticals. The costs for EGD, diagnostic procedures and physician services were obtained from the 2000 American Medical Association Current Procedural Terminology Code Book and the 2000 Medicare Fee Schedule. The costs were estimated using both actual data and authors' assumptions. The price year appears to have been 2000.
